Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.

Related Articles

Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.

QJM. 2016 Dec 22;:

Authors: Fountas A, Tigas S, Tsatsoulis A

PMID: 28011856 [PubMed - as supplied by publisher]

http://ift.tt/2i7dA5H